Inactivation of Chikungunya virus by 1,5 iodonapthyl azide
© Sharma et al.; licensee BioMed Central Ltd. 2012
Received: 24 May 2012
Accepted: 15 November 2012
Published: 4 December 2012
Chikungunya virus (CHIKV) is an arthropod borne alphavirus of the family Togaviridae. CHIKV is a reemerging virus for which there is no safe prophylactic vaccine. A live attenuated strain of CHIKV, CHIK181/25, was previously demonstrated to be highly immunogenic in humans, however, it showed residual virulence causing transient arthralgia.
In this study, we demonstrate the complete inactivation of CHIKV181/25 by 1,5 iodonapthyl azide (INA). No cytopathic effect and virus replication was observed in cells infected with the INA-inactivated CHIKV. However, a reduction in the INA-inactivated CHIK virus-antibody binding capacity was observed by western blot analysis.
INA completely inactivated CHIKV and can further be explored for developing an inactivated-CHIKV vaccine.
KeywordsChikungunya virus Inactivated vaccine Iodonapthyl azide
Earlier we have shown that 1,5 iodonapthyl azide (INA) and UV irradiation completely inactivated the Venezuelan equine encephalitis virus (VEEV)[1, 2]. In this study, we have extended that approach to evaluate the inactivation of Chikungunya virus (CHIKV). CHIKV is an arthropod borne alphavirus of the family Togaviridae. It is a reemerging virus that has caused wide spread outbreak in the nations surrounding the Indian Ocean and Africa since 2004. Among the alphaviruses, CHIKV is one of the most important human pathogens due to the frequent outbreaks worldwide, causing large scale morbidity and economic losses. CHIKV infection has been reported in the travelers returning from the epidemic regions, thereby indicating a potential of dissemination to the previously known naïve regions for CHIKV. Further, E1-A226V mutation in the CHIKV strain of 2005–2006 outbreak has increased the susceptibility of Aedes albopictus, which is endemic to the previously CHIKV naïve regions[5, 6]. Therefore, there is an ever increasing risk of CHIKV outbreak in the areas such as the United States of America, where CHIKV is not endemic. Such potential outbreak may be devastating due to lack of immunity to CHIKV in the endemic population. There are no specific drugs against CHIKV and patients are symptomatically treated with non steroid anti-inflammatory drugs. In the absence of antiviral drugs, preventive measures that include effective CHIKV vaccine are urgently needed. The United States Army had developed and tested a live attenuated strain of CHIKV, CHIKV181/25 for vaccine application. CHIKV181/25 demonstrated an excellent immunogenic profile (98% seroconversion), however, transient arthralgia was observed in about 8% of vaccine recipients. Several other approaches such as chimeric CHIKV on other alphavirus backbone, CHIK virus like particles, formalin inactivated CHIKV, DNA immunization and passive immunization with human polyvalent immunoglobulin have also been tested[9–13].
INA is a photoactive hydrophobic azide molecule that sequesters in the hydrophobic domain of the biomembranes and binds to the membrane proteins upon irradiation with long wavelength ultra-violet (UV) light. It was initially used for labeling the biological membranes. Interaction of INA with proteins inactivates the membrane protein while conserving the ectodomain protruding outside the membrane. This property of INA has been used to inactivate influenza virus, Ebola virus, VEEV, vaccinia virus, pixuna virus, simian and human immunodeficiency viruses and provide potential vaccine candidates[1, 2, 15–18]. In this study, we have evaluated the dose dependent inactivation of CHIKV181/25 by INA.
Our findings are important as CHIKV causes an ongoing outbreak affecting millions of people around the globe. An effective CHIKV vaccine is urgently needed to control the spread of CHIKV. Live attenuated CHIKV181/25 was shown to have an excellent immunogenicity; however, the clinical trial was halted due to issues with residual virulence causing transient arthralgia in the vaccine recipients. The INA-inactivated CHIKV181/25 formulation may address the issue of residual virulence that is associated with live attenuated CHIKV181/25. INA-inactivation resulted in a relatively less binding capacity of CHIKV181/25 to the neutralizing polyclonal anti-CHIKV E2 glycoprotein. This raises the question whether there may be some loss of antigenicity upon inactivation with INA. However, INA-inactivated CHIKV may still elicit a protective response against virulent CHIKV infection as shown with other INA-inactivated enveloped viruses such as VEEV, Ebola and Influenza virus. Chemical inactivation of CHIKV for vaccine purposes has been previously reported[11, 19]. Formalin inactivated CHIKV was shown to induce neutralizing antibody and reduce homologous virulent virus titer. Further testing of INA-inactivated CHIKV in the animal model will be needed for testing the protective efficacy of INA-inactivated CHIKV181/25 as a vaccine candidate, and its advantage over current approaches of generating inactivated vaccines. To our knowledge this is the first study to show a complete inactivation of CHIKV181/25 using INA.
1, 5 iodonapthyl azide
- BHK cells:
Baby hamster kidney cells
Phosphate buffered saline
Bovine serum albumin
Reverse Transcription-Polymerase chain reaction.
These studies were supported by JSTO-CBD/DTRA Contract/Grant/Intergovernmental Project Order/Project # 4.10019_07_US_B and USAMRIID contract No. G174QH. Authors acknowledge the technical help from Mr. Gautham Sukumaran and Mr. Raghavendar Chandran. INA was provided by Dr. Robert Blumenthal, CCR Nanobiology Program, Centre for Cancer Research, National Cancer Research Institute, Frederick, MD under MTA. The opinions or assertions contained herein are the scientific views of the authors and should not be construed as official or necessarily reflecting the views or policies of the Uniformed Services University of the Health Sciences or the Department of Defense, USA.
- Sharma A, Raviv Y, Puri A, Viard M, Blumenthal R, Maheshwari RK: Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem Biophys Res Commun 2007, 358: 392-398. 10.1016/j.bbrc.2007.04.115PubMedView Article
- Sharma A, Gupta P, Glass PJ, Parker MD, Maheshwari RK: Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development. Vaccine 2011, 29: 953-959. 10.1016/j.vaccine.2010.11.033PubMedView Article
- Das T, Jaffar-Bandjee MC, Hoarau JJ, Krejbich Trotot P, Denizot M, Lee-Pat-Yuen G, Sahoo R, Guiraud P, Ramful D, Robin S, Alessandri JL, Gauzere BA, Gasque P: Chikungunya fever: CNS infection and pathologies of a re-emerging arbovirus. Prog Neurobiol 2010, 91: 121-129. 10.1016/j.pneurobio.2009.12.006PubMedView Article
- Chen LH, Wilson ME: Dengue and chikungunya infections in travelers. Curr Opin Infect Dis 2010, 23: 438-444. 10.1097/QCO.0b013e32833c1d16PubMedView Article
- Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S: A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007, 3: e201. 10.1371/journal.ppat.0030201PubMedPubMed CentralView Article
- Martin E, Moutailler S, Madec Y, Failloux AB: Differential responses of the mosquito Aedes albopictus from the Indian Ocean region to two chikungunya isolates. BMC Ecol 2010.,10(8): 10.1186/1472-6785-10-8
- Chhabra M, Mittal V, Bhattacharya D, Rana U, Lal S: Chikungunya fever: a re-emerging viral infection. Indian J Med Microbiol 2008, 26: 5-12. 10.4103/0255-0857.38850PubMedView Article
- Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA: Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. AmJTrop Med Hyg 2000, 62: 681-685.
- Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, Weaver SC: Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26: 5030-5039. 10.1016/j.vaccine.2008.07.054PubMedPubMed CentralView Article
- Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ: A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med 2010, 16: 334-338. 10.1038/nm.2105PubMedPubMed CentralView Article
- Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV: Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009, 27: 2513-2522. 10.1016/j.vaccine.2009.02.062PubMedView Article
- Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB: Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 2008, 26: 5128-5134. 10.1016/j.vaccine.2008.03.060PubMedPubMed CentralView Article
- Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S, Prost JF, Lecuit M: Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis 2009, 200: 516-523. 10.1086/600381PubMedView Article
- Bercovici T, Gitler C: 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 1978, 17: 1484-1489. 10.1021/bi00601a020PubMedView Article
- Raviv Y, Viard M, Bess JW Jr, Chertova E, Blumenthal R: Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol 2005, 79: 12394-12400. 10.1128/JVI.79.19.12394-12400.2005PubMedPubMed CentralView Article
- Warfield KL, Swenson DL, Olinger GG, Kalina WV, Viard M, Aitichou M, Chi X, Ibrahim S, Blumenthal R, Raviv Y, Bavari S, Aman MJ: Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis 2007,196(Suppl 2):S276-S283.PubMedView Article
- Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M: Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008, 82: 4612-4619. 10.1128/JVI.02233-07PubMedPubMed CentralView Article
- Sagripanti J, Marschall H, Voss L, Hülseweh B: Photochemical Inactivation of Alpha- and Poxviruses. Photochem Photobiol 2003,87(6):1369-1378.View Article
- Kumar M, Arankalle VA: Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 2012, 30: 6142-6149. 10.1016/j.vaccine.2012.07.072PubMedView Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.